# OnCo record fortifi-hn01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/fortifi-hn01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "fortifi-hn01", "NCT06788990" ;
  schema:name "FORTIFI-HN01"@en ;
  schema:description "A bifunctional antibody that blocks EGFR and soaks up TGF-beta, aiming to make HPV-negative head and neck tumours respond to immunotherapy."@en ;
  schema:url <https://onco.cc/trials/fortifi-hn01/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06788990>, <https://ascopubs.org/doi/10.1200/JCO-25-02027> ;
  onco:status "recruiting" ;
  onco:phase "2/3" ;
  schema:startDate "2025-01-28" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/>, <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/ficerafusp-alfa/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/bicara-therapeutics/> .